Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. Indiana University Cancer Center, Indianapolis, IN, United States

Survival: 26.7 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: Indianapolis, IN
Hospital: Indiana University Cancer Center
Journal: Link
Date: 12/2007

Patients: This phase 3 study involved 722 women with metastatic breast cancer. They ranged in age from 27 to 85 years of age. The majority had estrogen receptor positive tumors.

Treatment: These women were treated with the chemotherapy drug paclitaxel alone or in combination with the biological therapy bevacizumab (a monoclonal antibody).

Toxicity: Grade 4 allergic reaction, fatigue, febrile neutropenia, cerebrovascular ischemia, and sensory neuropathy were reported. Grade 3 toxicities included allergic reaction, febrile neutropenia, infection, fatigue, hypertension, sensory neuropathy, and nausea.

Results: The median overall survival was 26.7 months in women receiving paclitaxel and bevacizumab and 25.2 months for those receiving paclitaxel alone.

Support: This study was supported in part by Genentech, which markets bevacizumab as Avastin“.

Correspondence: Dr. Kathy Miller

E-mail to a Friend Email Physician More Information